Metagenomi Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Metagenomi Therapeutics, Inc. (MGX) reported Increase Decrease In Operating Lease Liability of -$2.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.47M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.47M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.47M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.33M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$5.62M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$3.40M.
- Metagenomi Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.19M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.94M 10-Q · filed 2026-08-10 | -$4.41M derived: sum of 3 quarters · filed 2026-08-10 | -$5.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$1.47M 10-Q · filed 2026-05-11 | -$2.94M derived: sum of 2 quarters · filed 2026-05-11 | -$4.27M derived: sum of 3 quarters · filed 2026-05-11 | -$5.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.80M derived: sum of 2 quarters · filed 2026-03-05 | -$4.24M derived: sum of 3 quarters · filed 2026-08-10 | -$5.62M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.77M derived: sum of 2 quarters · filed 2026-08-10 | -$4.15M 10-Q · filed 2025-11-12 | -$5.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.82M 10-Q · filed 2026-08-10 | -$4.05M derived: sum of 3 quarters · filed 2026-08-10 | -$5.92M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$1.37M 10-Q · filed 2026-05-11 | -$2.60M derived: sum of 2 quarters · filed 2026-05-11 | -$4.47M derived: sum of 3 quarters · filed 2026-05-11 | -$4.59M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.10M derived: sum of 2 quarters · filed 2026-03-05 | -$3.22M derived: sum of 3 quarters · filed 2026-03-05 | -$3.40M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.99M derived: sum of 2 quarters · filed 2025-11-12 | -$2.17M 10-Q · filed 2025-11-12 | -$2.38M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$300.00K 10-Q · filed 2025-08-12 | -$514.00K derived: sum of 3 quarters · filed 2025-08-12 | -$769.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$179.00K 10-Q · filed 2025-05-13 | -$393.00K derived: sum of 2 quarters · filed 2025-05-13 | -$648.00K derived: sum of 3 quarters · filed 2025-05-13 | -$898.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$469.00K derived: sum of 2 quarters · filed 2025-03-17 | -$719.00K derived: sum of 3 quarters · filed 2025-03-17 | -$1.19M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$255.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$505.00K derived: sum of 2 quarters · filed 2024-11-13 | -$972.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$717.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$467.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |